Based on the Axsome Therapeutics Inc stock forecast from 18 analysts, the average analyst target price for Axsome Therapeutics Inc is USD 162.67 over the next 12 months. Axsome Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Axsome Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Axsome Therapeutics Inc’s stock price was USD 106.25. Axsome Therapeutics Inc’s stock price has changed by -3.99% over the past week, -3.55% over the past month and +48.50% over the last year.
No recent analyst target price found for Axsome Therapeutics Inc
No recent average analyst rating found for Axsome Therapeutics Inc
Company Overview Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura. It also develops AXS-05 (dextromethorphan-bupropion), an investigational N-methyl-D-aspartate receptor antagonist, which has completed Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, which has completed Phase III trial to treat narcolepsy; AXS-14 (esreboxetine), a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, which is in Phase III trial for treating attention deficit hyperactivity, major depressive, binge eating, and excessive sleepiness associated with shift work disorder. The company has a research collaboration agreement with Duke University for evaluating AXS-05 in a Phase 2 clinical trial in smoking cessation. Axsome Therapeutics, Inc. was incorporated in 2012 and is based in New York, New York. Read Less
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D...Read More
Frequently Asked Questions About Axsome Therapeutics Inc (AXSM) Stock
Based on ratings from 18 analysts Axsome Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 55 buy, sell and hold ratings.
Unfortunately we do not have enough data on AXSM's stock to indicate if its a good dividend stock.
Based on targets from 18 analysts, the average taret price for AXSM is USD 162.67 over the next 12 months. The maximum analyst target price is USD 216 while the minimum anlayst target price is USD 110.
Unfortunately we do not have enough data on AXSM's stock to indicate if its overvalued.
The last closing price of AXSM's stock was USD 106.25.
The most recent market capitalization for AXSM is USD 5.18B.
Based on targets from 18 analysts, the average taret price for AXSM is projected at USD 162.67 over the next 12 months.
This means that AXSM's stock price may go up by +53.10% over the next 12 months.
We can't find any ETFs which contains Axsome Therapeutics Inc's stock.
As per our most recent records Axsome Therapeutics Inc has 712 Employees.
Axsome Therapeutics Inc's registered address is One World Trade Center, New York, NY, United States, 10007.
You can get more information about it from Axsome Therapeutics Inc's website at https://www.axsome.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Axsome Therapeutics Inc (AXSM) Stock
Based on ratings from 18 analysts Axsome Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 55 buy, sell and hold ratings.
Unfortunately we do not have enough data on AXSM's stock to indicate if its a good dividend stock.
Based on targets from 18 analysts, the average taret price for AXSM is USD 162.67 over the next 12 months. The maximum analyst target price is USD 216 while the minimum anlayst target price is USD 110.
Unfortunately we do not have enough data on AXSM's stock to indicate if its overvalued.
The last closing price of AXSM's stock was USD 106.25.
The most recent market capitalization for AXSM is USD 5.18B.
Based on targets from 18 analysts, the average taret price for AXSM is projected at USD 162.67 over the next 12 months.
This means that AXSM's stock price may go up by +53.10% over the next 12 months.
We can't find any ETFs which contains Axsome Therapeutics Inc's stock.
As per our most recent records Axsome Therapeutics Inc has 712 Employees.
Axsome Therapeutics Inc's registered address is One World Trade Center, New York, NY, United States, 10007.
You can get more information about it from Axsome Therapeutics Inc's website at https://www.axsome.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AXSM !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
